Tenelit D Tablet is a clinically effective dual-drug oral formulation combining Dapagliflozin 10mg and Teneligliptin 20mg, designed to manage type-2 diabetes mellitus through complementary mechanisms of action. It is widely prescribed for patients requiring better glycemic control than monotherapy.
Dapagliflozin helps lower blood glucose by promoting urinary glucose excretion, while Teneligliptin enhances incretin activity, improving insulin secretion and reducing glucagon levels. Together, they provide balanced control of fasting and postprandial blood sugar levels with improved metabolic stability.
This combination is commonly recommended for patients with insulin resistance and impaired glucose regulation, offering effective glucose control with a favorable tolerability profile. Its once-daily dosing supports better patient compliance in long-term diabetes management.
Adding Tenelit D Tablet to your portfolio strengthens your diabetes and metabolic-care segment, creating strong opportunities in retail pharmacy supply, hospital procurement, institutional distribution, export markets, and third-party manufacturing. Its high prescription demand and chronic-therapy usage make it a commercially reliable product.